Surufatinib in Patients With Unresectable or Metastatic Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
Cancer 2021 Nov 01;127(21)3975-3984, J Xu, Y Bai, H Sun, C Bai, R Jia, Y Li, W Zhang, L Liu, C Huang, M Guan, J Zhou, W SuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.